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Abstract
Autosomal recessive mutations in the RARS2 gene encoding the
mitochondrial arginyl-transfer RNA synthetase cause infantile-onset
myoencephalopathy pontocerebellar hypoplasia type 6 (PCH6). We
describe 2 sisters with novel compound heterozygous RARS2 muta-
tions who presented perinatally with neurologic features typical of
PCH6 but with additional features including cardiomyopathy,
hydrops, and pulmonary hypoplasia and who died at 1 day and
14 days of age. Magnetic resonance imaging ﬁndings included
marked cerebellar hypoplasia, gyral immaturity, punctate lesions in
cerebral white matter, and unfused deep cerebral grey matter. Enzyme
histochemistry of postmortem tissues revealed a near-global cyto-
chrome c oxidase-deﬁciency; assessment of respiratory chain enzyme
activities conﬁrmed severe deﬁciencies involving complexes I, III, and
IV. Molecular genetic studies revealed 2 RARS2 gene mutations: a
c.1A9G, p.? variant predicted to abolish the initiator methionine, and a
deep intronic c.613-3927C9T variant causing skipping of exons 6Y8 in
the mature RARS2 transcript. Neuropathologic investigation included
low brain weights, small brainstem and cerebellum, deep cerebral white
matter pathology, pontine nucleus neuron loss (in 1 sibling), and pe-
ripheral nerve pathology. Mitochondrial respiratory chain immuno-
histochemistry in brain tissues conﬁrmed an absence of complexes I
and IV immunoreactivity with sparing of mitochondrial numbers. These
cases expand the clinical spectrum of RARS2 mutations, including
antenatal features and widespread mitochondrial respiratory chain
deﬁciencies in postmortem brain tissues.
Key Words: Mitochondrial disease, Pontocerebellar hypoplasia type 6,
RARS2, Respiratory chain deﬁciency.
INTRODUCTION
Mitochondrial respiratory chain diseases represent a
clinically and genetically diverse collection of isolated or
multiorgan disorders with an incidence estimated at 1 in 5000
births (1). Mutations in either mitochondrial or nuclear DNA
can lead to defective protein synthesis resulting in impaired
assembly and function of the oxidative phosphorylation sys-
tem and reduced adenine triphosphate biosynthesis. This can
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result in a wide range of phenotypes affecting both children
and adults. The increasing use of targeted exome sequencing
and next-generation sequencing has led to the identiﬁcation of
an expanding spectrum of mutations in nuclear encoded mi-
tochondrial proteins (2), including mitochondrial aminoacyl
transfer RNA (tRNA) synthetases (mt-aaRSs) (3).
All mt-aaRSs are translated in the cytosol before being
imported into the mitochondria where they play a key role in
mitochondrial protein translation by catalyzing the attachment of
amino acids to their cognate tRNA molecules. This is a 2-step
process by which the mt-aaRS activates 1 of the 20 amino acids
with adenine triphosphate to form an aminoacyl-adenylate in-
termediate, which then transfers the aminoacyl part to the cognate
tRNA. Once a tRNA is charged with its cognate amino acid, it
is delivered to the mitoribosome where the amino acid can be-
come incorporated into the growing polypeptide chain (4).
Defects in mt-aaRSs have emerged as an important cause
of perinatal or infantile onset respiratory chain diseases. These
are associated with autosomal recessive inheritance and are often
fatal in early life. Mutations in RARS2 (mitochondrial arginyl-
tRNA synthetase; 6q15) have been identiﬁed in children with
pontocerebellar hypoplasia type 6 ([PCH6]; OMIM#611523);
these were ﬁrst described in a consanguineous Sephardic Jewish
family in which affected children presented with intractable
seizures, hypotonia, profound neurodevelopmental delay, mi-
crocephaly, and feeding difﬁculties (5). Neuroimaging revealed
progressive cerebellar atrophy with cerebral involvement. Each
affected child was homozygous for an intronic c.110+5A9G
mutation leading to aberrant mRNA splicing and associated with
respiratory chain defects in muscle and ﬁbroblasts. An additional
16 patients harboring autosomal recessive RARS2 mutations
have since been reported (6Y10); detailed postmortem neuro-
pathologic reports are only available for 2 cases (11). These
cases demonstrated additional features of PCH subtypes 2 and
4, including severe dystonia, optic atrophy, and thinning of the
corpus callosum (9). In addition to the PCH, anterior horn cell
disease was also found at autopsy, a ﬁnding typically associated
with PCH1 (7).
Here we report 2 siblings with a PCH6 presentation in
whom, in addition to the characteristic pontocerebellar hypo-
plasia and microcephaly, there was evidence of cardiomyopathy
and peripheral neuropathy. We show that this fatal neurologic
disease was due to novel compound heterozygous RARS2 muta-
tions, including the ﬁrst deep intronic recessive mutation to
cause fatal pediatric mitochondrial disease, and describe the
neuropathologic characteristics in postmortem brain tissue from
both clinically affected siblings.
MATERIALS AND METHODS
This study had relevant ethical approval from the in-
stitutional review board of Newcastle University and com-
plied with the Declaration of Helsinki, and written informed
consent was obtained.
Patients
Patient I-1
A female was born at 36 weeks to nonconsanguineous
healthy, UK Caucasian British parents following a normal
pregnancy and delivery. Birth weight was 2.470 kg (25thY50th
centile); head circumference was 32.5 cm (50thY75th centile). On
delivery, general condition was immediately and unexpectedly
poor, with Apgar scores of 1 at 1 minute and 1 at 5 minutes. She
was blue, ﬂoppy, and took only 1 breath. She was intubated
at birth, and resuscitation was attempted for over an hour but
was ultimately unsuccessful. Apart from a dermal pit on the
lower back, no dysmorphic features were noted on examination.
Patient I-2
This pregnancy was closely monitored because of the
previous neonatal death. Nuchal translucency was increased
on ultrasound at 12 weeks (3.8 mm; 99th centile, 3.5 mm
[12]). Because of concerns about fetal bradycardia, serial fetal
echocardiograms were performed, which, at 20 weeks gesta-
tion, revealed mild biventricular hypertrophy in the absence of
left or right outﬂow obstruction. From 29 weeks on the ven-
tricular hypertrophy was more marked on the right than the
left and was nonprogressive. Ultrasonography revealed trans-
verse cerebellar diameter at 18.9 mm at 20+2 weeks and 19.5mm
at 21+2 weeks on the 3rd percentile. Biparietal diameter was
43.8 and 49.6 mm at corresponding dates. Repeat ultrasound
scan at 36 weeks showed polyhydramnios, right-sided pleural
effusion, hyperechogenic bowel loops with bowel dilation, skin
edema, and absence of fetal movements.
Labor was induced at 36+2 weeks, with vaginal delivery
of a cyanotic, hypotonic, and bradycardic female weighing
2.340 kg (25th centile). APGAR scores were 3 at 1 minute
and 4 at 5 minutes. Assisted ventilation rapidly improved both
heart rate and color. She was intubated by 6 minutes of age
because of absence of echocardiogram movements and absent
respiratory effort. She remained ventilator dependent. Post-
natal echocardiogram conﬁrmed biventricular hypertrophy
with good ventricular function and neither left nor right ven-
tricular outﬂow obstruction. Neurologic examination revealed
marked central and peripheral hypotonia, decreased reﬂexes
and minimal spontaneous limb movements. No dysmorphic
features were noted. Ocular and audiologic examinations were
normal. On day 2, EEG suggested burst-suppression pattern.
Blood and CSF lactate levels were elevated (blood persis-
tently È7 mmol/L with maximum 19.8 mmol/L on day 11
[reference range, 0.7Y2.2 mmol/L], CSF 11.3 mmol/L on day 5
[reference range, 1.1Y2.2 mmol/L]). She had low serum calci-
um on day 1 treated with intravenous calcium infusion and
hyponatremia during the ﬁrst week managed by ﬂuid re-
striction. Urinary analyses showed moderate lactic aciduria,
moderately increased 4-hydroxyphenylacetate, and mildly in-
creased 4-hydroxyphenylpyruvate, consistent with liver dys-
function/immaturity. Cranial magnetic resonance imaging (MRI)
was performed on day 8. After family discussion, intensive
care was withdrawn on day 14, and death rapidly occurred. A
full postmortem examination was conducted 1 day later with
full consent.
Muscle Histology, Histochemistry, and
Respiratory Chain Activity
Standard histologic and histochemical analyses of post-
mortem skeletal muscle and cardiac tissue were performed on
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fresh-frozen 10-Km-thick cryosections. Standard methods in-
cluded hematoxylin and eosin (H&E) stain, modiﬁed Gomori
trichrome stain, and sequential cytochrome c oxidase/succinate
dehydrogenase (COX/SDH) histochemistry to assess both com-
plex IV (COX) and complex II (SDH) activities (13). Activities
of individual respiratory chain complexes (IYIV) and citrate
synthase were measured spectrophotometrically, as previously
described (14).
Molecular Genetic Investigations
Genomic DNA was extracted from patient muscle biopsy
according to standard protocols. Primer 3 was used to design
primers speciﬁc to each coding exon of RARS2 (Figure, Sup-
plemental Digital Content 1, http://links.lww.com/NEN/A746).
Patient genomic DNA was polymerase chain reaction (PCR)
ampliﬁed and Sanger sequenced using BigDye v3.1 chemistry
(Applied Biosystems, Cheshire, UK) and capillary electropho-
resis performed on an ABI3130xl platform (Applied Biosystems)
(15). Patient sequencing chromatograms were compared with
the Genbank reference sequence (NM_020320.3) and all vari-
ants were annotated using dbSNP build 138. Allele frequency
of all gene variants was determined using ESP6500 and 10k
genome project data. Parental DNA samples were referred to
conﬁrm a recessive inheritance of detected variants.
Complimentary DNA (cDNA) was derived from whole
RNA extracted from patient ﬁbroblasts cultured in standard
Dulbecco modiﬁed eagle medium. Preservation of abnormal
mRNA transcripts was accomplished by culturing conﬂuent pa-
tient ﬁbroblasts overnight in emetine-containing media at a ﬁnal
concentration of 100 Kg/mL before harvesting (16). Reverse
transcription of 2 Kg RNA was performed using GoScript re-
verse transcription system and a poly dT primer (Promega,
Hampshire, UK). PCR ampliﬁcation of 2 overlapping cDNA
fragments and electrophoresis of PCR ampliﬁed products through
a 2% agarose gel facilitated identiﬁcation of normal and ab-
normal length cDNA fragments.
Gel excision of cDNA fragments was performed using
the Agarose Gel DNA Extraction Kit (Roche, Welwyn,
Garden City, UK), according to the manufacturer’s protocol
and recovered amplicons were subject to DNA sequencing. In
silico splicing prediction tools NNSPLICE, Human Splicing
Finder, and MaxEnt were used to investigate the likely im-
pact of a putative splicing variant in intron 8 identiﬁed by
cDNA studies.
Neuropathology
Postmortem intervals for Patients I-1 and I-2 were 5 days
and 1 day, respectively. After removal of the CNS, frontal and
occipital brain samples from Patient I-2 were snap-frozen and
kept atj80-C for long-term storage. Peripheral sciatic nerve
tissues were also sampled and processed for electron mi-
croscopy. For both Patient I-1 and I-2, the remaining CNS
was ﬁxed in formalin for 7 and 11 days, respectively, and parafﬁn
embedded before undergoing routine neuropathologic examina-
tion (14). To document the severity of the pathologic changes
in patient tissues, CNS tissues from 2 disease controls were
obtained from the Newcastle Brain Tissue Resource (Table,
Supplemental Digital Content 2, http://links.lww.com/NEN/A747).
Histology and immunohistochemistry were performed as pre-
viously described (14).
Mitochondrial Respiratory Chain Enzyme
Histochemistry and Immunohistochemistry
Sequential COX/SDH histochemistry was undertaken
on 10-Km-thick frozen sections of frontal and occipital cortex
from Patient I-2, as previously described (17). Distribution
and expression of key subunits of the mitochondrial respira-
tory chain complexes (complexes IYIV) and porin (a marker
of mitochondrial number) were analyzed using immunohis-
tochemistry performed on 5-Km formalin-ﬁxed, parafﬁn-
embedded frontal, parietal, temporal, and occipital cortices,
basal ganglia, pons, and cerebellum, as previously described
(14). To allow a direct comparison, patient and control tissues
were included in all experiments.
RESULTS
Cranial MRI
Cranial MRI on Day 8 of Patient I-2 showed markedly
decreased cerebellar diameter at 33 mm, reduced vermian
height at 10.9 mm (Fig. 1A), and slightly decreased antero-
posterior pontine diameter at 10 mm but with normal shape. No
cerebellar cysts were identiﬁed. Cerebrum showed punctate
foci in lobar white matter (Fig. 1B); corpus callosum and
splenium were within normal limits; there were simple gyri
with a possible area of polymicrogyria within 1 Sylvian ﬁssure.
Lateral ventricles were prominent. There was no midline fusion
of either deep grey matter or cortical ribbon (Fig. 1C).
General Autopsy
Patient I-1
The head circumference was 32.5 cm (50thY75th centile).
External gross examination showed no facial or other dysmorphism.
Internal gross ﬁndings consisted of bilateral pleural effusions,
hypoplastic lungs; the heart was normal. Microscopically, liver
and kidney were normal.
Patient I-2
Head circumference was 32.0 cm (50thY75th centile).
External gross examination revealed generalized subcutaneous
edema, small midface, wide lower face, and depressed nasal
bridge; limbs, hands, and feet were normal. There were peri-
cardial, pleural, peritoneal effusions. Lungs were hypoplastic.
The heart showed prominent right ventricular trabeculation with
FIGURE 1. Cranial MRI performed on Patient I-2 at age 8 days and effect of RARS2 mutation on COX activity in postmortem skeletal
muscle and heart sections. (A) Sagittal T1-weighted image demonstrating hypoplastic cerebellar vermis. (B) Transverse T1-weighted
images illustrating punctate white matter signal changes (white arrows). (C) Coronal T1-weighted image illustrates no midline fusion
of the deep grey matter or cortical ribbon. (D) COX/SDH histochemistry of patient tissues reveals a generalized loss of COX activity in
both skeletal muscle and cardiac tissues. Scale bar = 100 Km.
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FIGURE 2. Molecular characterization of novel RARS2 mutations. (A) Sequencing of the RARS2 coding region identiﬁed a novel
heterozygous c.1A9G RARS2 variant predicted to abolish the initiating methionine (p.Met1?). (B) PCR and electrophoretic analysis
of RARS2 cDNA derived from the proband’s ﬁbroblasts revealed 2 populations, a wild-type amplicon plus an amplicon demon-
strating skipping of exons 6Y9. (C) Sequencing of a gel-puriﬁed cDNA amplicon clearly shows skipping of exons 6Y9 in RARS2
patient cDNA. (D) cDNA analysis of ﬁbroblasts cultured in emetine-containing media reveal a novel transcript (asterisk). Sanger
sequencing of this band following agarose gel excision revealed retention of 112 bp of intronic sequence (Figure, Supplemental
Digital Content 1, http://links.lww.com/NEN/A746). (E) Sequencing of surrounding genomic DNA revealed a novel c.613-
3927C9T substitution upstream of the retained intronic sequence, which create a cryptic splicing acceptor at c.613-3916_613-
3915; together with a cryptic splicing donor site at c.613-3793_613-3792, this causes the retention of 112 bp of intron 8 (Figure,
Supplemental Digital Content 1, http://links.lww.com/NEN/A746).
TABLE. Assessment of Respiratory Chain Complex Activities in Postmortem Skeletal and Cardiac Muscle Homogenates From
Patient I-2
Complex I/CS Complex II/CS Complex III/CS Complex IV/CS
Patient I-2 (muscle) 0.019 0.105 0.155 0.051
Controls (n = 25) 0.104 T 0.036 0.145 T 0.047 0.554 T 0.345 1.124 T 0.511
Patient I-2 (cardiac) 0.008 0.072 0.167 0.015
Controls (n = 25) 0.125 T 0.048 0.152 T 0.050 1.112 T 0.386 1.258 T 0.367
Enzyme activities are expressed as nmol NADH oxidized minj1.unit citrate synthase (CS)j1 for complex I, nmol DCPIP reduced minj1.unit citrate synthasej1 for complex II
(succinate:ubiquinone-1 reductase) and the apparent ﬁrst-order rate constant.secj1.unit citrate synthasej1 for complexes III and IV (103). Control values are shown as mean T SD.
DCPIP, 2,6-dichlorophenol-indophenol.
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a thickened (0.9 cm) free ventricular wall. The left ventricle
showed less trabeculation, but there was slight thickening of
the free wall (1.2 cm); the myocardium was pale. The liver
showed centrilobular congestion with focal cholestasis, micro-
steatosis, and lipid vacuolation of some hepatocytes. Renal tu-
bules featured occasional Oil Red OYpositive lipid vacuoles.
Muscle and Cardiac Morphology, Histochemistry,
and Biochemistry
Patient I-1
Cardiac muscle featured instances of myocyte central
clearing and abundant eosinophilic cytoplasmic puncta interpreted
as mitochondria, some abnormally large, overall considered con-
sistent with a mitochondrial cardiomyopathy. Oil Red O stain did
not show accumulation of ﬁne-droplet lipid in any myoﬁber.
Patient I-2
Microscopically, the heart showed myocyte hypertro-
phy without disarray. Some myocytes were swollen with
perinuclear clearing and loss of cross-striation; contained nu-
merous eosinophilic dots interpreted as mitochondria, some
being abnormally large; and had an excess of ﬁne droplets of
Oil Red OYpositive lipid. There was no inﬂammation, ne-
crosis, or endocardial ﬁbroelastosis.
COX/SDH histochemistry revealed a near global loss
of COX activity despite sparing of SDH activity in both skel-
etal and cardiac muscle tissues from both patients (Fig. 1D).
Although the postmortem interval was longer in Patient I-1
(5 days), it is our experience that samples retain COX and
SDH activity after considerable postmortem delay and it is
usually SDH activity that is most labile. Spectrophotometric
assay of mitochondrial respiratory chain complexes showed
a marked reduction in complex I, III, and IV activities in
Patient I-2’s skeletal and cardiac muscle compared with con-
trols with a general sparing of complex II activity, indicating
a generalized defect of mitochondrial translation (Table).
Molecular Genetics
The combination of radiologic cerebellar atrophy and
multiple mitochondrial respiratory chain defects strongly sug-
gest the diagnosis of PCH6 (OMIM 611523) due to recessive
mutations in the RARS2 gene (5). In conﬁrmation, sequencing
the entire coding region and intron-exon boundaries of the
RARS2 gene was performed for Patient I-2, revealing a single
heterozygous c.1A9G variant that is predicted to abolish the
initiator methionine, thereby resulting in a null allele (Fig. 2A).
No further known or potentially pathogenic RARS2 variants
were identiﬁed in the coding region. cDNA investigations using
ﬁbroblast-derived RNA from Patient I-2 provided evidence
of aberrant mRNA splicing with the presence of 2 differen-
tially sized RARS2 cDNA molecules, the wild-type transcript
harboring the c.1A9G variant and a second transcript ap-
parently lacking exons 6, 7, and 8 (Figs. 2B, C). Repeating
the cDNA investigations using ﬁbroblasts cultured in eme-
tine, an inhibitor of mitochondrial translation, revealed a number
of additional transcripts. One retained 123 bp of intronic sequence
from intron 8, c.613-3916_613-3793 (Fig. 2D). Analysis of the
surrounding genomic sequence revealed a novel c.613-3927C9T
variant upstream of the retained sequence (Fig. 2E; Figure, Sup-
plemental Digital Content 1, http://links.lww.com/NEN/A746),
supporting creation of a cryptic splice acceptor. In silico in-
vestigations predict a very high score for the c.613-3916
cryptic splice acceptor site. The aberrantly spliced mRNA
transcript that lacks exons 6Y8 results in a frame-shift mutation.
Analysis of familial DNA samples conﬁrmed that both
sisters harbored the paternal c.1A9G, p.? and maternal c.613-
3927C9T RARS2 variants, thereby conﬁrming recessive in-
heritance. Prenatal testing of a chorionic villus sample for
these variants in a third pregnancy revealed neither RARS2
variant and a healthy child was born.
Neuropathology
Patient I-1
The ﬁxed brain was micrencephalic weighing 257 g (refer-
ence range, 366 T 50 g, n = 11 for 36Y37weeks gestation [18]). The
combined cerebellum and brainstem weight of 11.5 g was simi-
larly low for the age (reference range, 21.4 g T 3.36 g). Externally,
the gross appearance of forebrain and hindbrain was normal,
and the cerebellar vermis and hemispheres were normally formed
without any evidence of atrophy. Coronal sectioning of the
hemispheres showed cortical pallor, consistent with ischemia-
hypoxia, with lobar white matter discoloration without cystic
degeneration or mineralization. The corpus callosum, fornix,
septum pellucidum, and internal capsule were normal. The deep
grey matter was unremarkable and without mineralization. The
hippocampi were normal with mild compression in the lateral
ventricles. The third ventricle was normal and there was no fu-
sion across the midline. The midbrain aqueduct was compressed
in the vertical plane, suggestive ofmild cerebral swelling. Tectum
and peduncles were normal. Cerebellum was sectioned horizon-
tally and lacked distinct dentate nuclei. Medulla and pons were
grossly normal.
Microscopically, the cerebellar cortex revealed focal de-
pletion of neurons from the external granular cell layer, an ab-
normally thin molecular layer, and sparsely populated internal
granular cell layer. Purkinje cell numbers were markedly re-
duced, with the remainder exhibiting a shrunken perikarya and
eosinophilia (Fig. 3Bi). Calbindin-staining demonstrated the
perikaryal change and added severe stunting of apical den-
drites, with an absence of ‘‘cactus bodies’’ (dystrophic den-
dritic structures) (Fig. 3Biv). The dentate nucleus ribbon, best
identiﬁed by synaptophysin immunoreactivity (Fig. 3Cii), had
a normal undulating conﬁguration but was abnormally thin and
was very sparsely populated by neurons in H&E stain (Fig. 3Ci).
In the medulla, synaptophysin immunostaining likewise dem-
onstrated a normally formed neuropil ribbon for the inferior
olivary nuclei, whereas H&E stain demonstrated its constitu-
ent neurons (Figs. 3Di, ii). Pyramidal and other long tracts
appeared normal. The basal pontine nuclei contained normal
neuron complement, although rare karyorrhectic bodies were
identiﬁed (Fig. 4Bi). Basal pontine transverse ﬁbers could not be
demonstrated using antiphosphorylated neuroﬁlament immuno-
histochemistry (Fig. 4Ci) contrasting with the positive immu-
noreactivity in the medial longitudinal fasciculus (Fig. 4Cii) and
medial lemniscus (Fig. 4Ciii). The midbrain had a distinct red
nucleus, but decussation of superior cerebellar peduncle could
not be demonstrated. The cerebral aqueduct, cerebral peduncles,
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and colliculi were normal. Although the hippocampi were nor-
mally formed, there was minor subicular neuronal karyorrhexis,
microgliosis, and astrocytosis. Putamen, caudate, globus pallidus,
and thalamus had normal neuronal complement, cytology, and
neuropil consistency and did not show any mineralization. By
immunohistochemistry, only the globus pallidus and lateral nuclei
of the thalamus showed diffuse microgliosis; there was no
astrocytosis. The optic tract and posterior limb of internal cap-
sule appeared normal. The cerebral white matter was con-
gested but lacked periventricular leukomalacia or other acquired
abnormalities and the corpus callosum was normal. The neo-
cortex demonstrated normal neuronal complement and cytolo-
gy and no mineralization was observed.
Patient I-2
The ﬁxed brain weighed 230 g, whereas the combined
brainstem and cerebellum weight was disproportionately low at
10.4 g (4.5% of total ﬁxed brain weight). Externally, cerebral
leptomeninges loosely covered a normal arrangement of gyri
where there was no sulcal widening. The medulla and cerebel-
lum were much smaller relative to the remainder of the brain.
Coronal sections of cerebrum showed neither sulcal widening
nor malformation; however, macroscopically, there was dark
discoloration of the central white matter with superimposed pale
streaks within the occipital region (Fig. 4Di). The corpus
callosum was of normal thickness, the anterior commissure and
fornix were normal, and the septum pellucidum was caved
anteriorly but otherwise normal. The deep grey matter showed
no midline fusion. The hippocampi appeared normally formed
and largely ﬁlled the temporal horns; the lateral and third
ventricles were not dilated. The midbrain showed a normal
aqueduct, peduncles, and colliculi. Pons had grossly normal
tegmentum and basis pontis, whereas the medulla was tiny.
Cerebellar vermis and hemisphere showed fewer folial sub-
divisions than normal (Figs. 3Ai, ii). A 5-cm sample of lower
spinal cord displayed no convincing abnormalities.
Microscopic ﬁndings were generally similar to or
supplemented those in the sibling. Sagittal sections through the
cerebellar vermis clearly demonstrated a normal arrangement of
principal lobules but much reduced folial branching (Fig. 3Ai).
The marked reduction in thickness of individual cortical lami-
nae, lack of Purkinje cells (Fig. 3Biii) and their cytologic
changes (Fig. 3Bv), and reduced internal granule-cell packing-
density were as in Patient I-1. The dentate nucleus and the
internal olivary nuclei were both discernible and normally
formed (Figs. 3Ciii and Diii, iv). The basis pontis of Patient I-2,
however, contrasted strikingly with her sister’s by displaying
marked neuron loss (Fig. 4Bii) associated with astrogliosis
(Fig. 4Biii), and microgliosis (Fig. 4Biv). Deep cerebral white
matter showed mineralizing macrophage-rich foci of periven-
tricular leukomalacia (Fig. 4Dii), corresponding to the macro-
scopic streaky pallor. The putamen, caudate, and globus pallidus
exhibited sparse eosinophilic neurons consistent with ischemia-
hypoxia, capillary prominence, and endothelial cell hypertrophy
without excessive micromineralization. Immunohistochemistry
for glial ﬁbrillary acidic protein showed astrocytosis in the
globus pallidus alone, whereas anti-CD68 showed moderate and
minor microgliosis in globus pallidus and caudate-putamen, re-
spectively. The hypothalamus showed normal nuclear groups
and mammillary bodies, dorsolateral regions showed moderate
diffuse microgliosis, and there was no astrocytosis. In contrast
to Patient I-1, the internal capsule and optic tract showed mod-
erate microgliosis.
Sciatic nerve (available for Patient I-2 only) showed rare
small CD68-positive macrophages and similarly immunoreactive
sparse spindly cells within the endoneurium by light microscopy.
Phosphorylated neuroﬁlament antibody showed axons of all sizes
(Figs. 5A, B). There were no cellular inﬁltrates. Electron mi-
croscopy, although hampered by postmortem artefact, demon-
strated considerably fewer myelinated ﬁbers than expected for
the age (Figs. 5C, D). Some myelinated ﬁbers had an inappro-
priately thin sheath for axon diameter. In some others, the axon
was absent, leaving only a collapsed myelin sheath. A few un-
myelinated axons were large enough to be the result of demye-
lination, whereas the perineurium appeared mature, which does
not suggest delayed maturation.
Mitochondrial Pathology in CNS Tissues
Mitochondrial densities, as judged by porin and nuclear-
encoded SDHA immunoreactivity, were high in neurons
throughout all CNS tissues analyzed. Immunohistochemical anal-
ysis of mitochondrial respiratory chain protein expression showed
evidence of a speciﬁc and total loss of subunits comprising com-
plex I, as judged by a lack of immunoreactivity for subunits
NDUFB8 and NDUFS3, throughout all CNS tissues investigated
in both Patients I-1 and I-2. This was prominent in the cerebellum
where cell loss was severe (Fig. 6), the pontine nucleus (Fig. 7),
and in other regions where neuronal population density was intact,
including the occipital cortex (Fig. 8) and other brain regions,
including frontal cortex and basal ganglia (Figure, Supplemental
Digital Content 3, http://links.lww.com/NEN/A748). Analysis of
the other mitochondrial respiratory chain complexes revealed
comparable immunoreactivity of complexes II and III to that
observed in control tissues; however, the mitochondrially
encoded COX1 was absent despite high immunoreactivity for
COX4 of this complex. This loss of protein expression is selec-
tive for complexes I and COX1 throughout the brain and sug-
gestive of respiratory chain deﬁciency due to decrease or absence
FIGURE 3. Histopathologic ﬁndings in the cerebellar tissues from Patient I-1 and I-2. (A)Macroscopically, the delayed development
of the cerebellum is prominent in Patient I-2 (i) compared with an age-matched control (ii, H&E). (B) At a higher magniﬁcation,
there is a marked reduction in Purkinje cells by H&E in both patients (I-1 = i, I-2 = ii) relative to an age-matched control (iii). Where
Purkinje cells were present in Patient I-1 (iv) and Patient I-2 (v), they exhibited stunted apical dendrites compared with those in an
age-matched control (vi). Calbindin immunohistochemistry. (C) The dentate nucleus was detected in both cases although the
neuronal population density was reduced in Patient I-1 (i) and I-2 (iii), and the neuropil ribbon was thin (I-1, ii, synaptophysin). (D)
The inferior olivary nuclei were present in both cases with intact neuronal population density shown with H&E in Patient I-1 (i) and
Patient I-2 (iii). Neuropil ribbons are demonstrated in Patient I-1 (ii, synaptophysin) and I-2 (iv, synaptophysin). Scale bar = 100 Km.
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FIGURE 4. Histopathologic ﬁndings in the pons and occipital lobe tissues from Patient I-1 and I-2. (A) Macroscopic assessment of
H&E-stained pons from Patient I-2 (i) revealed severe atrophy compared to an age-matched control (ii). (B) In a pontine nucleus in
Patient I-1, there is relatively intact neuronal cell density (Luxol Fast Blue with Cresyl Fast Violet [LFB/CFV]) (i), whereas there was
marked neuronal cell loss in Patient I-2 (ii, LFB/CFV) accompanied by astrogliosis (iii, glial ﬁbrillary acidic protein immunohisto-
chemistry [IHC]) and microgliosis (iv, CD-68 IHC), which was in contrast to normal neuronal density in an age-matched control (v,
LFB/CFV). (C) In addition, there is a profound loss of phosphorylated neuroﬁlaments in axons corresponding to the pontocerebellar
ﬁbers in Patient I-1 (i, SMI-31R IHC) in contrast to intact expression in medial longitudinal fasciculus (ii) and medial lemniscus (iii).
(D) Deep white matter abnormalities were observed in the occipital lobe (i), consistent with the hyperintensity seen on neuro-
imaging; microscopically, this corresponded to the presence of mineralized axons (ii, H&E). Scale bar = 100 Km.
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of expression of these components despite abundant mitochon-
dria in these regions.
DISCUSSION
We present only the second autopsy series of neonatal
pontocerebellar hypoplasia type 6 (PCH6) in 2 siblings born
to nonconsanguineous parents. In the neonatal period, the
siblings were hypotonic, lacked spontaneous respiratory ef-
fort, and deteriorated rapidly, leading to death on Day 1 and
Day 14, respectively. Biochemical analysis of skeletal and
cardiac muscle conﬁrmed extensive respiratory chain deﬁciency
involving complexes I, III, and IV, and enzyme histochemistry
showed a complete loss of COX activity. Mitochondrial respi-
ratory chain complex-speciﬁc immunohistochemistry conﬁrmed
a lack of immunoreactivity for complexes I and IV despite a high
density of mitochondria throughout the CNS. This supports a
generalized loss of respiratory chain activity due to a translation
defect and is in agreement with previous ﬁndings with variable
respiratory chain defects in muscle from patients with RARS2
mutations (5, 10). Molecular genetic investigations identiﬁed a
paternally inherited single heterozygous c.1A9G mutation that
is predicted to abolish translation initiation. Despite the iden-
tiﬁcation of just 1 heterozygous RARS2 variant, the certain
pathogenicity meant that it was highly likely that PCH6 was
the clinical diagnosis in tandem with a second, latent RARS2
variant. This initiated cDNA studies that led to the identiﬁcation
of a cDNA transcript lacking exons 6Y8 due to a maternally
FIGURE 5. Sciatic nerve pathology in Patient I-2. (A, B) IHC revealed an irregular distribution and reduced number of large axons in
the sciatic nerve (neuroﬁlament IHC). (C, D) Electron microscopy revealed loss of myelin surrounding axons [A] and the presence of
degenerating ﬁbers (*), which are observed alongside intact axons. Scale bars: A, B, 100 Km; C, 1 Km; D, 2 Km.
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inherited novel, deep-intronic variant, c.613-3927C9T, which
activates a cryptic splice site. In addition to reporting 2 novel
RARS2 mutations, this study expands upon the clinical phe-
notypes and neuropathology associated with RARS2 mutations
in this rare autosomal recessive mitochondrial disease.
The canonical features of PCH6 detected in Patient I-2
included early-onset encephalopathy, raised lactate levels in
blood and CSF, pontocerebellar hypoplasia (observed on MRI
and conﬁrmed by neuropathologic examination), and com-
bined defects in oxidative phosphorylation (5, 7, 9, 10). In
addition, we report features not previously associated with
PCH6 including fetal echocardiograph ﬁndings consistent
with a hypertrophic cardiomyopathy phenotype and hydrops
fetalis. Cardiomyopathy was detected at 20 weeks gestation
following concerns regarding fetal bradycardia and was as-
cribed to biventricular hypertrophy. Despite being a new
ﬁnding in association with RARS2 mutations, cardiomyopathy
is a common clinical feature in other mitochondrial disease
presentations in which neonatal presentation of the hypertro-
phic type (HCM) is associated with a high mortality (19). The
high rate of mortality might reﬂect the metabolic shift from
prenatal anaerobic glycolysis to postnatal metabolism that is
driven by fatty acid oxidation, ketone catabolism, and oxida-
tive phosphorylation (20). Primary mutations affecting mito-
chondrial DNA and mutations in the nuclear-encoded alanyl-
tRNA synthetase (AARS2),MTO1, and GTBP3 genes have also
been implicated in severe infantile, prenatal-onset cardiomy-
opathy presentations with combined respiratory chain deﬁ-
ciencies (21Y23). In addition to HCM, pulmonary hypoplasia
was also reported in the patients described by Gotz et al and
was thought to be secondary to the cardiac hypertrophy (23).
In view of the neuroradiologic imaging supporting the
clinical diagnosis of PCH6, sequence analysis of the RARS2
gene was undertaken. Sixteen PCH6 patients with recessive
RARS2 mutations have been reported to date, with missense
variants being the major class (24). There is a paucity of
truncating mutations, highlighting the importance of the full-
length, functional transcript although splicing variants have
accounted for 1 allele in 10 patients. No patient reported to date
has presented with 2 null RARS2 alleles, and this is reﬂected
also in this family. The c.1A9G variant is predicted to entirely
abolish the translation of the corresponding allele, whereas we
hypothesize that the allele harboring the deep intronic splicing
variant is predicted to confer some (albeit minimal) residual
activity due to some normal transcript remaining. This would
explain the limited compatibility with life that was observed in
the clinically affected children of this family.
As a mutational mechanism, deep intronic variants are
likely to be under-represented in the literature, possibly as a
consequence of strategies employed in current genetic testing.
First, genomic DNA is often the source for diagnostic se-
quencing investigations; therefore, splicing variants may re-
main undiagnosed unless they affect the consensus splicing
donor or acceptor sites at +/j2 bp of the exon boundary;
variants situated beyond +/j 10 bp of the exon/intron
boundaries are often regarded as of ‘‘uncertain signiﬁcance.’’
Exome-based, next-generation sequencing strategies share the
same bias, although cDNA-based next-generation sequencing
strategies and whole genome sequencing will hopefully elu-
cidate the prevalence of both splicing variants and large-scale
gene rearrangements. The deep intronic RARS2 variant was
only apparent following emetine-induced nonsense mediated
decay arrest; the abnormal transcript was subject to nonsense
mediated decay in normal culture conditions, leaving only a
transcript lacking exons 6Y8 in the mRNA corresponding to the
maternal allele. This variant, although not subject to nonsense
mediated decay, is likely to give rise to a nonfunctional, trun-
cated protein. To our knowledge, only 1 deep intronic mutation
has been reported previously in association with any mito-
chondrial disease presentationVa dominant OPA1 mutation
that causes progressive optic atrophy in adulthood (25). In
addition to describing the ﬁrst deep intronic recessive muta-
tion in a fatal pediatric mitochondrial disease presentation, this
study highlights the utility of cDNA investigations, particularly
in patients with only 1 candidate mutation in a recessively in-
herited disease.
There is only 1 illustrated report of PCH6 neuropathology
describing 2 cases (11), and 1 very brief description as part of
a broader survey of pontocerebellar hypoplasia (7). Therefore,
our ﬁndings double the number of neuropathologic de-
scriptions of this condition and provide the ﬁrst record of pe-
ripheral nerve pathology.
Our ﬁndings are similar to those of Joseph et al (11) in a
number of respects but also reveal some signiﬁcant differ-
ences. We found that the brains of our patients were also
micrencephalic and the cerebellar vermis displayed much-
simpliﬁed foliation, corresponding, at a rough estimate (26),
to that of a 114-mm crown-rump (È18 week gestation) fetus
and indicating an element of developmental delay, or arrest,
that began in utero, in agreement with previous ﬁndings (11).
The pons was abnormally small and basal pontine nucleus
neurons were severely decreased in number in Patient I-2 but
were within normal limits in Patient I-1. The small size of the
pons might be attributed to delayed development, whereas
neuronal cell loss might reﬂect regressive degeneration because
of the presence of astrogliosis and microgliosis. Evidence in
support of regressive degeneration is provided by the sibling
who died only 1 hour after birth and who demonstrated intact
neuronal density in the pontine nucleus. This was also veriﬁed by
Joseph et al, where very few neurons were noted in this structure
in both twins. This suggests that RARS2 mutations adversely
affect the pons and cerebellum and that the neurons within these
structures are particularly vulnerable to degeneration. In fact,
vulnerability of the developed cerebellum to perturbed mito-
chondrial function is particularly common (27Y29). In these
cases, however, it is likely to be a direct consequence of a
FIGURE 6. Mitochondrial respiratory chain deﬁciency in the cerebellum of Patients I-1 and I-2. Immunohistochemical staining of
components of the mitochondrial respiratory chain revealed severe, combined respiratory chain deﬁciencies in remaining cells in-
volving complex I (NDUFB8) and themitochondrially encoded complex IV subunit I (COX1), despite preservation of complex II (SDHA)
and complex III core 2 (UQCRC2) expression and the mitochondrial mass marker porin in serial sections. Scale bar = 100 Km.
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mismatch between mitochondrial protein synthesis and the ac-
celerated growth phase of the cerebellum during late gestation,
rendering the cerebellum particularly susceptible (30).
We also provide further evidence corroborating deep white
matter pathology in the occipital poles both radiologically and
histopathologically that is comparable with the ﬁndings of Joseph
FIGURE 7. Mitochondrial respiratory chain deﬁciencies in the pontine nucleus. The mitochondrial respiratory chain proteins in-
vestigated showed high immunoreactivity in an age-matched control (right panels). Patient I-2 shows a profound absence of
immunoreactivity for complexes I (NDUFB8) and IV (COX1), indicating respiratory chain deﬁciency. Scale bar = 100 Km.
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FIGURE 8.Mitochondrial respiratory chain deﬁciency in the occipital cortex. Neuron population densities were intact in Patient I-2
and control tissues (H&E). Immunohistochemical staining for components of the mitochondrial respiratory chain revealed a marked
loss of complex I in Patient I-2 (NDUFB8) vs control (NDUFB8), and mitochondrially encoded subunit of complex IV (COX1) vs
control (COX1), indicating complex I and IV deﬁciencies. Complex II (SDHA) and a nuclear-encoded subunit of complex IV (COX4)
expression levels were preserved in conjunction with high mitochondrial density (porin) in both patient and control neurons. Scale
bar = 100 Km.
J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015 Clinical, Genetic, and Pathologic Aspects of PCH6
 2015 American Association of Neuropathologists, Inc. 701
et al, with discoloration, extensive gliosis, and few neuro-
ﬁlaments. Since both of our patients exhibited clinical com-
plications associated with poor ventilation due to respiratory
insufﬁciency, we cannot exclude the effects of hypoxic-ischemic
injury contributing to the presence of karyorrhectic neurons in
the pons and subiculum, eosinophilic neurons in the basal
ganglia, and also periventricular leukomalacia. This was not a
striking feature of the patients described by Joseph et al, but it
remains an important consideration when evaluating the neu-
ropathology since these are often features that emerge after se-
vere hypoxic-ischemia (31).
We observed additional novel features not previously
documented in PCH6 that expand on the neuropathologic fea-
tures of the disorder. In both siblings, we identiﬁed the cere-
bellar dentate nucleus and inferior olivary nucleus, although we
recognize the former demonstrated reduced neuronal cell den-
sity and gliosis. We were also able to identify a red nucleus,
which was gliotic in Patient I-1. MRI in our cases did not reveal
midline fusion of cerebral deep white matter and conﬁrmed a
full corpus callosum with well-formed splenium, in contrast to
the ﬁndings of Joseph et al. Another important novel ﬁnding
was the evidence of reduced axonal packing density and ab-
normally thin myelin sheaths in the peripheral nerve, which has
not previously been described in PCH6.
Mitochondrial respiratory chain complex-speciﬁc im-
munohistochemistry was investigated in CNS tissues for the
ﬁrst time in both patients. This analysis revealed profound and
rather selective complex I and IV deﬁciency, involving com-
plex I subunits NDUFB8 and NDUFS3 and mitochondrially
encoded COX1. This pattern of respiratory chain deﬁciency
was widespread and not just restricted to the brainstem and
cerebellum where the greatest pathology was evident.
The present study expands on the disease-causing variants
ofRARS2, provides further evidence of the clinical heterogeneity
associated with RARS2 mutations, and augments the neuro-
pathologic features associated with PCH6. Our data expand on
the pathogenesis of PCH6 disease caused by RARS2 mutations
and provide further characterization of the speciﬁc temporal and
regional degeneration in patients with this rare disorder. Neuro-
nal tissue is exquisitely sensitive to deregulation of protein
synthesis, and even more so during the postmigratory phase of
neuronal development when the demand for protein synthesis is
high. Although we understand that RARS2 encodes for an en-
zyme that aminoacylates mt-tRNAArg in mitochondria, we do
not fully understand why mutations in this gene cause a speciﬁc
pattern of neurodegeneration leading to PCH6. We can speculate
on the mechanisms based on TSEN54 and RARS2 knockdown
studies performed in zebraﬁsh in which overlapping pheno-
types are observed implying a shared mechanism of degener-
ation (32). Based on this, we speculate that the demand for
mitochondrial arginyl-tRNA synthetase is particularly high dur-
ing the development of certain tissues, including the ponto-
cerebellar and cardiac tissues. Indeed, the cerebellum undergoes a
rapid phase of growth during late gestation, that is, at 28 weeks
postconception, which could explain the speciﬁc vulnerability of
this brain region to impaired RARS2 function in patients har-
boring RARS2 mutations (30).
Establishing a genetic diagnosis for families with mi-
tochondrial respiratory chain dysfunction is crucial in the
process of genetic counseling enabling a correct recurrence
risk to be provided and reproductive options including pre-
natal diagnosis or preimplantation genetic diagnosis. Once 2
deleterious RARS2 gene variants were identiﬁed, the parents
of the patients in this report opted for analysis of a chorionic
villus biopsy in a subsequent pregnancy. Our analysis showed
that the fetus harbored neither of the familial RARS2 muta-
tions and a healthy boy has since been born.
ACKNOWLEDGMENTS
The authors thank Dr E. Hook and Dr A. Whitehead for
their help in the general pathological assessment, and biomedical,
medical-photographic and secretarial staff at Addenbrooke’s
Hospital for excellent support.
REFERENCES
1. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mi-
tochondrial respiratory chain disorders in children. Brain 2003;126:
1905Y12
2. Taylor RW, Pyle A, Griffin H, et al. Use of whole-exome sequencing to
determine the genetic basis of multiple mitochondrial respiratory chain
complex deficiencies. JAMA 2014;312:68Y77
3. Diodato D, Ghezzi D, Tiranti V. The mitochondrial aminoacyl tRNA
synthetases: genes and syndromes. Int J Cell Biol 2014;2014:787956
4. Smits P, Smeitink J, van den Heuvel L. Mitochondrial translation and
beyond: processes implicated in combined oxidative phosphorylation
deficiencies. J Biomed Biotech 2010;2010:737385
5. Edvardson S, Shaag A, Kolesnikova O, et al. Deleterious mutation in the
mitochondrial arginyl-transfer RNA synthetase gene is associated with
pontocerebellar hypoplasia. American J Hum Gen 2007;81:857Y62
6. Rankin J, Brown R, Dobyns WB, et al. Pontocerebellar hypoplasia type
6: A British case with PEHO-like features. AmJ Med Gen Part A 2010;
152A:2079Y84
7. Namavar Y, Barth PG, Kasher PR, et al. Clinical, neuroradiological and
genetic findings in pontocerebellar hypoplasia. Brain 2011;134:143Y56
8. Kastrissianakis K, Anand G, Quaghebeur G, et al. Subdural effusions and
lack of early pontocerebellar hypoplasia in siblings with RARS2 muta-
tions. Arch Dis Child 2013;98:1004Y7
9. Glamuzina E, Brown R, Hogarth K, et al. Further delineation of
pontocerebellar hypoplasia type 6 due to mutations in the gene encoding
mitochondrial arginyl-tRNA synthetase, RARS2. J Inher Metab Dis
2012;35:459Y67
10. Cassandrini D, Cilio MR, Bianchi M, et al. Pontocerebellar hypoplasia
type 6 caused by mutations in RARS2: definition of the clinical spec-
trum and molecular findings in five patients. J Inher Metab Dis 2013;
36:43Y53
11. Joseph JT, Innes AM, Smith AC, et al. Neuropathologic features of
pontocerebellar hypoplasia type 6. J Neuropathol Exp Neurol 2014;73:
1009Y25
12. Wright D, Kagan KO, Molina FS, et al. A mixture model of nuchal
translucency thickness in screening for chromosomal defects. Ultrasound
Obstet Gynecol 2008;31:376Y83
13. Old SL, Johnson MA. Methods of microphotometric assay of succinate
dehydrogenase and cytochrome c oxidase activities for use on human
skeletal muscle. Histochem J 1989;21:545Y55
14. Lax NZ, Gnanapavan S, Dowson SJ, et al. Early-onset cataracts, spastic
paraparesis, and ataxia caused by a novel mitochondrial tRNAGlu (MT-TE)
gene mutation causing severe complex I deficiency: a clinical, molecular, and
neuropathologic study. J Neuropathol Exp Neurol 2013;72:164Y75
15. Untergasser A, Cutcutache I, Koressaar T, et al. Primer3Vnew capa-
bilities and interfaces. Nucleic Acids Res 2012;40:e115
16. Noensie EN, Dietz HC. A strategy for disease gene identification through
nonsense-mediated mRNA decay inhibition. Nature Biotechnol 2001;19:
434Y9
17. Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of MELAS:
level of heteroplasmy in individual neurones and evidence of extensive
vascular involvement. Neuropathol Appl Neurobiol 2006;32:359Y73
Lax et al J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015
 2015 American Association of Neuropathologists, Inc.702
18. Guihard-Costa AM, Larroche JC. Differential growth between the fetal
brain and its infratentorial part. Early Hum Devel 1990;23:27Y40
19. Schiff M, Ogier de Baulny H, Lombes A. Neonatal cardiomyopathies and
metabolic crises due to oxidative phosphorylation defects. Sem Fetal
Neonatal Med 2011;16:216Y21
20. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the
cardiomyocyte during development, differentiation, and postnatal matu-
ration. J Cardiovasc Pharm 2010;56:130Y40
21. Kopajtich R, Nicholls TJ, Rorbach J, et al. Mutations in GTPBP3 cause a
mitochondrial translation defect associated with hypertrophic cardiomyopa-
thy, lactic acidosis, and encephalopathy. Am J Hum Gen 2014;95:708Y20
22. Ghezzi D, Baruffini E, Haack TB, et al. Mutations of the mitochondrial-tRNA
modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. Am
J Hum Gen 2012;90:1079Y87
23. Gotz A, Tyynismaa H, Euro L, et al. Exome sequencing identifies mito-
chondrial alanyl-tRNA synthetase mutations in infantile mitochondrial
cardiomyopathy. Am J Hum Gen 2011;88:635Y42
24. Grefsheim SF, Whitmore SC, Rapp BA, et al. The informationist:
building evidence for an emerging health profession. J Med Libr Assoc
2010;98:147Y56
25. Bonifert T, Karle KN, Tonagel F, et al. Pure and syndromic optic atrophy
explained by deep intronic OPA1 mutations and an intralocus modifier.
Brain 2014;137:2164Y77
26. Larsell O, Jansen J, Korneliussen HK, Mugnaini E. The Comparative
Anatomy and Histology of the Cerebellum: The Human Cerebellum, Cer-
ebellar Connections, and Cerebellar Cortex. Minneapolis, MN. Minnesota
University Press, 1972
27. Hakonen AH, Goffart S, Marjavaara S, et al. Infantile-onset spinocerebellar
ataxia and mitochondrial recessive ataxia syndrome are associated with
neuronal complex I defect and mtDNA depletion. Hum Molec Gen 2008;
17:3822Y35
28. Quintana A, Kruse SE, Kapur RP, et al. Complex I deficiency due
to loss of Ndufs4 in the brain results in progressive encephalopathy
resembling Leigh syndrome. Proc Natl Acad Sci USA 2010;107:
10996Y1001
29. Lax NZ, Hepplewhite PD, Reeve AK, et al. Cerebellar ataxia in patients
with mitochondrial DNA disease: a molecular clinicopathological study.
J Neuropathol Exp Neurol 2012;71:148Y61
30. Limperopoulos C, Soul JS, Gauvreau K, et al. Late gestation cerebellar growth
is rapid and impeded by premature birth. Pediatrics 2005;115:688Y95
31. Lai MC, Yang SN. Perinatal hypoxic-ischemic encephalopathy. J Biomed
Biotechnol 2011;2011:609813
32. Kasher PR, Namavar Y, van Tijn P, et al. Impairment of the tRNA-splicing
endonuclease subunit 54 (tsen54) gene causes neurological abnormalities
and larval death in zebrafish models of pontocerebellar hypoplasia. Hum
Molec Gen 2011;20:1574Y84
J Neuropathol Exp Neurol  Volume 74, Number 7, July 2015 Clinical, Genetic, and Pathologic Aspects of PCH6
 2015 American Association of Neuropathologists, Inc. 703
